Blood transfusions at home

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm pilot at Thomas Jefferson University Hospital offering home blood draws and same-day transfusions for adults with hematologic malignancies or marrow failure who are transfusion dependent. Participants receive 1-2 blood products per week for up to five weeks (total of up to 5 transfusions), with staff documenting barriers to delivering transfusions in the home. Data are collected through surveys at each visit, end-of-intervention participant surveys, and semi-structured qualitative interviews. The protocol excludes patients with prior transfusion reactions, significant heart failure, or unstable housing, and limits enrollment to those living within 30 miles of the Center City SKCCC location.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:
* Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study
* Male or female, over the age of 18
* Must meet definition of transfusion dependence (require at least 2 blood product transfusions over a 28-day period)
* Receive their cancer care at SKCCC
* Have a history of blood product transfusions and NO history of transfusion reactions,
* Live within a 30-mile range of the Center City SKCCC location.
* Must be willing to allow people into the home

Exclusion Criteria:

* An individual who meets any of the following criteria will be excluded from participation in this study:
* Patients who have a history of a transfusion reaction
* Heart failure as defined by AHA stage C or NYHA Class II-IV
* Non-English or Spanish speaking
* Are unhoused
* Are incarcerated
* Have poor venous access
* Diagnosis of Solid Tumor malignancy
* Women who are pregnant

Where it's running

• Thomas Jefferson University Hospital
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Adam Binder, MD — Adam.Binder@jefferson.edu
• Study coordinator: Adam Binder, MD
• Email: Adam.Binder@jefferson.edu
• Phone: 215-955-8874

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

• Evaluating TGRX-814 in patients with blood cancers

  This study is testing a new drug called TGRX-814 to see if it is safe and effective for people with blood cancers like lymphoma and leukemia.

  Recruiting Phase 1/2 Shenzhen TargetRx Co., Ltd. · Tianjin, Tianjin Municipality · NCT06206174

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.